Development of σ-receptor ligands and clinical trials

T. Nabeshima, I. Muraoka

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


There are at least two classes of σ-receptors, termed σ1 and σ2. Recently, the σ1-receptor has been completely sequenced in different species. The amino acid sequences of the different purified proteins are highly homologous, but it shares no homology to know mammalian proteins. These results suggest that the σ1 receptor is a distinct entity from any often known receptors, σ-Receptors are involved in many physiological functions. Therefore, σ-ligands show many different pharmacological effects such as glucose utilization, neuroprotective, antipsychotic, antidepressive, anxiolytic, nootropic, antiepileptic, antiabuse, antitussive, antidiarrhea, anti-inflammatory, tear protein releasing stimulant and central anti- micturition reflex actions. These results suggest that σ-receptors are very promising targets for the development of new drugs that have new mechanisms of action.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalFolia Pharmacologica Japonica
Issue number1
Publication statusPublished - 1999
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology


Dive into the research topics of 'Development of σ-receptor ligands and clinical trials'. Together they form a unique fingerprint.

Cite this